Skip to search boxSkip to navigationSkip to main content

Beneficial Effects of a CaMKIIα Inhibitor TatCN21 Peptide in Global Cerebral Ischemia

  • Mohammad Ejaz Ahmed
    ,
  • Yan Dong
    ,
  • Yujiao Lu
    ,
  • Donovan Tucker
    ,
  • Ruimin Wang
    ,
  • Quanguang Zhang(corresponding author)
*Corresponding author for this work
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Abstract

Aberrant calcium influx is a common feature following ischemic reperfusion (I/R) in transient global cerebral ischemia (GCI) and causes delayed neuronal cell death in the CA1 region of the hippocampus. Activation of calcium-calmodulin (CaM)-dependent protein kinase IIα (CaMKIIα) is a key event in calcium signaling in ischemic injury. The present study examined the effects of intracerebroventricular (icv) injection of tatCN21 in ischemic rats 3 h after GCI reperfusion. Cresyl violet and NeuN staining revealed that tatCN21 exerted neuroprotective effects against delayed neuronal cell death of hippocampal CA1 pyramidal neurons 10 days post-GCI. In addition, TatCN21 administration ameliorated GCI-induced spatial memory deficits in the Barnes maze task as well as anxiety-like behaviors and spontaneous motor activity in the elevated plus maze and open field test, respectively. Mechanistic studies showed that the administration of tatCN21 decreased GCI-induced phosphorylation, translocation, and membrane targeting of CaMKIIα. Treatment with tatCN21 also inhibited the level of CaMKIIα-NR2B interaction and NR2B phosphorylation. Our results revealed an important role of tatCN21 in inhibiting CaMKIIα activation and its beneficial effects in neuroprotection and memory preservation in an ischemic brain injury model.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 42-51 (10 pages)

Journal (Volume, Issue Number)

Journal of Molecular Neuroscience (Volume 61, Issue 1)

Publication milestones

  • Accepted/In press - 09/07/2016
  • Published - 01/01/2017

Publication status

Published - 01/01/2017

ISSN

0895-8696

Publication IDs

  • Scopus: 84986269064
  • PubMed: 27604243

Publication metrics

Metrics

SciVal
citations
13
Fractional count
1
Fractional count
0.17
Fractional count
5
Fractional count
0.83
Fractional count
1
Fractional count
1
Scopus
citations
SciVal
FWCI
0.71
SciVal
Author count
6
SciVal
Paper percentile
81

PlumX, opens in new tab

Captures
21
Citation count
29

Funding Details

This study was supported by Research Grant NS086929 from the National Institute of Neurological Disorders and Stroke, National Institutes of Health, USA, and the American Heart Association Grant-in-Aid 15GRNT25240004.
FundersFunding numbers
NIH
-
NINDS
R01NS086929
AHA
15GRNT25240004